Sihuan Pharmaceutical

Hainan Sihuan Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company focused on the research and development, manufacture, and sales of pharmaceutical products in China. Founded in 2001 the company headquarters are in Beijing.

Sihuan Pharmaceutical Holdings Group was incorporated in Bermuda in April 2006 and was successfully listed in Singapore in March 2007. In 2009, due to greater growth, Sihuan Pharmaceutical Holdings Group completed privatization and was delisted from Singapore, before being successfully re-listed in Hong Kong in 2010.

Since its founding the company has incorporated Beijing Sihuan Pharmaceutical, Shenzhen Sihuan Pharmaceutical, and other companies, developing into a pharmaceutical group with integrated R&D, production and sales capabilities. Sihuan has 4 R & D platforms, 11 production sites, and 8 sales companies located around China.

Sihuan's portfolio includes Kelinao, Anjieli and Oudimei drugs used for diseases related to the cardio-cerebral vascular (CCV) system, central nervous system, metabolism, and oncology.

A clinical trial of oral favipiravir, developed by Sihuan Pharmaceutical, is to investigate the drug’s potential against coronavirus (COVID-19). Favipiravir is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus.

The trial is being led by Beijing Chaoyang Hospital and is part of a program by Sihuan and the Institute of Microbiology Epidemiology, a division of the Chinese armed forces. The parallel dose exploration study will enroll 60 cases of regular COVID-19, for a treatment period of 10 days. The firm says it will initiate efficacy and safety verification trials of a larger-scale once results are obtained.